Incyte
(NASDAQ:INCY)
$52.94
0.89[1.71%]
At close: May 1
$52.94
0[0.00%]
After Hours: 4:00PM EDT
Q1 2024 Earnings were released on Tue Apr 30th, before the market open
The most recent conference call was at 8:00 AM, 1 day ago Click to view past webcast
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest
62.5%
Overview Rating
Good
Technicals Analysis
66
0100
Financials Analysis
60
0100

Incyte Stock (NASDAQ:INCY), Quotes and News Summary

Incyte Stock (NASDAQ: INCY) stock price, news, charts, stock research, profile.

Open$51.870
Close$52.940
Volume / Avg.3.576M / 1.841M
Day Range51.750 - 53.980
52 Wk Range50.270 - 75.740
Market Cap$11.887B
P/E Ratio15.776
Dividend Yield-
ExchangeNASDAQ
RSI
42
Short Interest
5.75%
Days to Cover4.59

Recent News

Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow.
Vandana Singh
Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B
Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat.
Vandana Singh
MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer
Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold as part of a profit-sharing agreement with Incyte, which saw net product sales of $92 million in 2023. MorphoSys also is developing Pelabresib, an inhibitor of proteins involved in the development and progression of myelofibrosis.
Erica Kollmann
60%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
3
2
Feb
1
Mar
1
1
Apr
2
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
2.6
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Compare

EPS better than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
INCY
LEGN

FAQ

Q

How do I buy Incyte (INCY) stock?

A

You can purchase shares of Incyte (NASDAQ: INCY) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Incyte's (INCY) competitors?

A

Other companies in Incyte’s space includes: Legend Biotech (NASDAQ:LEGN), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX) and Cerevel Therapeutics Hldg (NASDAQ:CERE).

Q

What is the target price for Incyte (INCY) stock?

A

The latest price target for Incyte (NASDAQ: INCY) was reported by TD Cowen on Wednesday, May 1, 2024. The analyst firm set a price target for 80.00 expecting INCY to rise to within 12 months (a possible 51.11% upside). 45 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Incyte (INCY)?

A

The stock price for Incyte (NASDAQ: INCY) is $52.94 last updated Today at May 1, 2024 at 4:00 PM EDT.

Q

Does Incyte (INCY) pay a dividend?

A

There are no upcoming dividends for Incyte.

Q

When is Incyte (NASDAQ:INCY) reporting earnings?

A

Incyte’s Q2 earnings are confirmed for Tuesday, July 30, 2024.

Q

Is Incyte (INCY) going to split?

A

There is no upcoming split for Incyte.

Q

What sector and industry does Incyte (INCY) operate in?

A

Incyte is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch